Wells Fargo & Company Raises Revvity (NYSE:RVTY) Price Target to $110.00

Revvity (NYSE:RVTY) had its target price hoisted by equities researchers at Wells Fargo & Company from $107.00 to $110.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 6.18% from the company’s current price.

A number of other equities analysts have also weighed in on RVTY. Weiss Ratings reiterated a “sell (d)” rating on shares of Revvity in a research note on Monday, December 29th. The Goldman Sachs Group assumed coverage on Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price objective on the stock. Robert W. Baird increased their price objective on Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 28th. Guggenheim began coverage on Revvity in a report on Wednesday, October 15th. They set a “neutral” rating for the company. Finally, Bank of America cut shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 target price for the company. in a research report on Monday, December 15th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $113.67.

Revvity Stock Performance

NYSE RVTY opened at $103.60 on Tuesday. The firm has a 50-day moving average of $103.97 and a 200-day moving average of $95.63. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.68. The stock has a market cap of $11.75 billion, a PE ratio of 49.81, a P/E/G ratio of 2.14 and a beta of 1.07. Revvity has a 52-week low of $81.36 and a 52-week high of $124.10.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, February 2nd. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. Revvity’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, sell-side analysts anticipate that Revvity will post 4.94 EPS for the current year.

Revvity announced that its board has authorized a stock buyback program on Monday, October 27th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to buy up to 8.7% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently bought and sold shares of the company. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 26.3% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock worth $751,536,000 after acquiring an additional 1,784,620 shares in the last quarter. Norges Bank acquired a new position in Revvity during the second quarter valued at approximately $124,574,000. Allspring Global Investments Holdings LLC lifted its stake in Revvity by 127.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company’s stock worth $171,921,000 after purchasing an additional 980,142 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Revvity by 39.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,125,957 shares of the company’s stock valued at $186,307,000 after purchasing an additional 596,436 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Revvity by 25.8% in the 2nd quarter. Invesco Ltd. now owns 2,207,202 shares of the company’s stock valued at $213,481,000 after purchasing an additional 452,343 shares in the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: TD Cowen raised its price target to $124 and kept a “buy” rating — a sizable ~20% upside vs. the recent price, signaling strong analyst conviction after the quarter. TD Cowen raise Benzinga
• Positive Sentiment: Wells Fargo lifted its target to $110 with an “equal weight” call, another upgrade that narrows downside risk. Wells Fargo raise
• Positive Sentiment: JPMorgan raised its target to $105 and maintained a “neutral” rating — a modest lift but further evidence of analyst re-rating after the results. JPMorgan raise
• Positive Sentiment: Revvity reported better-than-expected Q4 results and raised FY2026 guidance (EPS $5.35–5.45), which is the primary catalyst for upgrades and the improved momentum trade. Analysts boost forecasts
• Positive Sentiment: Zacks highlights Revvity as a strong momentum stock based on style scores, which can attract momentum-driven flows. Zacks momentum piece
• Neutral Sentiment: Investor commentary remains mixed; a Seeking Alpha piece calls Revvity “close to a buy” but cautious on valuation/risks, suggesting some analysts still see work to be done. Seeking Alpha
• Neutral Sentiment: Full earnings-call transcripts and deeper analyses (MSN/Yahoo) are available for investors wanting detail on segment performance, margin drivers, and guidance assumptions. MSN transcript Yahoo transcript
• Neutral Sentiment: A valuation-focused note examines recent share weakness vs. DCF gaps — useful for longer-term investors assessing whether upgraded targets leave room for upside. Yahoo valuation analysis

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.